New York City Metropolitan Area
As a results-focused and highly accomplished executive leader with unique combination of medical device and diagnostic business experience, I leverage data and analysis to provide strategic value, while driving operational excellence, to bring competitive advantage to the organization. I have strong experience driving P&L growth and revenue-generation activities. I enjoy building meaningful relationships, setting unified direction for team, and instilling a high standard of excellence throughout the teams and organizations I serve. I strive to create a culture with an innovation and growth mindset to help teams solve intractable problems. • Top Line Revenue & Gross Margin Growth • Medical Device and Diagnostic Product Management • Strategic Planning & Performance Innovation • Dynamic Organizational Leadership and Development Top Line Revenue & Gross Margin Growth Led high-profile, complex initiatives for Becton Dickinson (BD) as Vice President and General Manager Specimen Management Division. Grew business 12% in 2021 by leading strategic, targeted marketing efforts, program upgrades, and pricing increases to achieve competitive share gains. Medical Device Product Management Accelerated global growth in senior leadership position in healthcare and medical technology, including spearheading high-performance innovation incorporating connected devices and informatics. Managed BD’s $1.8B worldwide diagnostics business. Strategic Planning & Performance Innovation Initiated development of key innovation programs, including next-generation blood testing technology and traceability solutions. Established key external partnerships to augment internal capabilities. Dynamic Organizational Leadership and Development Created and motivated high-performing teams focused on accountability for performance outcomes. Served as transparent leader with strengths in cross-functional collaboration and communication.
Leads Qorvo’s biotechnology products, development, prototyping, planning, procurement, quality, production and sales. Executes biosensor strategy which includes scaling COVID-19 antigen test, growing our COVID, combination Flu/COVID and non-COVID testing business and distribution channels, driving long-term biotech innovation, and building a dependable and scalable operation positioned for future growth and market leadership.
Led business with top-line revenue of $1.8B with accountability for profit, manufacturing, quality, marketing, and revenue-generating activities in matrix environment. Chair management committee and oversee operational effectiveness of supply, quality, compliance, sales, regulatory, manufacturing, innovation, finance, and R&D. • Created first business development function and executed eight new agreements, including Labcorp, Roche, Truvian Sciences, and others expected to double revenue. − Delivered $100M in incremental revenue from new product programs. • Restructured management team to identify talent able to focus on new product development milestones. − Hired new R&D, quality, and medical affairs leaders to fulfill business objectives. − Improved new product development milestone delivery from 65% to 95% through more predictable product development process. •Led largest largest business group to grow 12% for 2021 BDX Business of the Year
Led worldwide marketing with cross-functional accountability for revenue, operating profit, and operating income, as well as manufacturing, regulatory, medical affairs, quality, supply chain, and sales functions for global pre-analytical system business with $1.6B in global sales. • Drove pricing excellence to achieve worldwide sustainable price increases of 0.5% in FY19, 1.1% in FY20, and 2% in FY21, including negotiating with leading customers to include HPG, Labcorp, Quest, Vizient, and Sonic. • Led restructuring of product lifecycle management to address quality and capacity issues. Created three-part strategy and led kaizen activities to manage business through 13% backorder by driving improvements in supply chain and initiating $350M investment over four years to resolve capacity issues. • Raised three-year growth targets from 4% to 6% by identifying and resourcing four new sources of growth.
General Manager for Becton Dickinson’s fastest growing platform. Led marketing and cross functional team, including regional marketing, regulatory, manufacturing, quality, medical affairs, sustaining engineering, and R&D to drive to business results. Developed annual business planning process [C2CC] driving market segmentation strategy and regional marketing planning to accelerate growth in all regions. Drove significant competitive share gains in US and Canada through competitive positioning and good tender management. Ensured seamless connection between capacity investment, supply planning, demand planning, and regional marketing to manage business at 0% surge and eliminate backorders. Managed significant business continuity risks in China related to both CFDA regulatory changes and reimbursement/pricing to maintain accelerated growth. • Increased Global revenue from $250M to $387M, averaging 15% annual growth, including 23% outside of the US, hitting 2018 target in 2016. • Increased profitability from 49.7% to 59.1% through pricing discipline, cost reduction, and growth in high price markets. • Changed long-term outlook on platform potential by expanding the defined market and accelerated strategic growth from 6.6% to 11.2%.
Directed $500M revenue-generating business reporting to VP of Marketing. Drove distribution, pricing, and marketing strategy and identified reimbursement trends. • Developed and executed through Corporate Account Directors and headquarters sales force, new channel strategy for non-acute centers. Initiative led to over 200 new contracted sites for the non-acute market. • Launched new hospital pricing strategy with simplified contracting. Developed new pricing strategy for non-acute market, delivering 110% growth in this new market.
Led $350M US endovascular business, including self-expanding stents and balloon expandable stents. Oversaw marketing interface with US sales force. Launched new products and help develop new procedure in carotid stenting with first to world FDA clearance and associated reimbursement.